SINGAPORE, April 28, 2025 /PRNewswire/ -- Gravity Game Hub (GGH) PTE. LTD., a subsidiary of GRAVITY Co., Ltd. (NasdaqGM: GRVY), is thrilled to announce the Second Closed Beta Test (CBT 2) for the legendary artillery game, Gunbound. Following the excitement of the first CBT, the second round is set to launch from [April 28 to May 07, 2025], reigniting the passion of fans across Latin America and Southeast Asia
Gunbound, beloved for its strategic gameplay and deep customization options, invites both returning and new players to experience fresh updates, competitive challenges, and exclusive CBT 2 rewards.
"We were overwhelmed by the response from our community during the first CBT. For CBT 2, we've focused on refining gameplay and fixing key issues to bring the ultimate Gunbound experience closer to launch," said Harry Choi, President of Gravity Game Hub (GGH).
What to Expect in the Second Closed Beta Test?
CBT 2 brings further improvements and exciting new content, including:
- Enhanced stability and gameplay balancing based on player feedback from the first CBT.
- More diverse mobile selections and avatar customization options.
- Jewel Fortune Box, An opportunity to test your luck and obtain exclusive rewards
Exclusive Rewards and Events During CBT 2
Players joining CBT 2 can look forward to even more engaging rewards and community events:
- Pre Top-up Rebate Event, Earn rewards with every top-up made during this period.
- Treasure Key, Log in via the website to obtain a Gunbound Key equivalent 50$
Note: All progress, items, and characters from CBT 2 will be RESET before the official launch.
How to Participate in Gunbound CBT 2
Joining is easy! Just follow the steps below:
Stay Connected for Updates
Get the latest news, patch notes, and community events through our official channels:
About Gravity Game Hub
Established in 2021, Gravity Game Hub (GGH) Pte. Ltd. is a game publisher and developer focusing on online and mobile games. Gravity Game Hub is committed to delivering an interactive gaming experience and creating a dynamic community for all players in Southeast Asia.
About Softnyx
Founded in April 2001, Softnyx has spent the past 20 years releasing a diverse range of online games, including Gunbound, Rakion, and WolfTeam. The company has established a unique gaming world enjoyed by 50 million users across 60 countries worldwide. As a pioneer in the Latin American gaming market, Softnyx has sparked the Korean wave through its relentless spirit of challenge and innovation, solidifying its status as a global gaming company.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Gunbound Rises Again – 2nd Closed Beta Goes Live for Latin America and Southeast Asia
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
